AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1993631 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole 2 g/m2 with 5.0 Gy x 6 fractions
Number of subjects: 859
Study 1993631 — intervention group
Group type: COMPARATOR
Intervention: 3.0 Gy x 10 fractions without Misonidazole
Number of subjects: 859
Study 1993631 — intervention group
Group type: COMPARATOR
Intervention: 5.0 Gy x 6 fractions without Misonidazole
Number of subjects: 859
Study 6524276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of 60 ml mepivacaine 1% with adrenaline
Number of subjects: 60
Study 6524276 — intervention group
Group type: COMPARATOR
Intervention: Fractional injections of 30 + 30 ml mepivacaine 1% with adrenaline (20 min interval)
Number of subjects: 60
Study 6524276 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Bolus and Fractional injections)
Number of subjects: 60
Study 31048271 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist implemented educational treatment programme
Number of subjects: 154
Study 31048271 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 154
Study 29027034 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity LED therapy (λ 640 ± 20 nm, 6 J/cm2)
Number of subjects: 40
Study 29027034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PG)
Number of subjects: 40
Study 27392872 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring using wearable sensors in conjunction with standard care
Number of subjects: 40
Study 27392872 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 40
Study 27392872 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring using wearable sensors
Number of subjects: 40
Study 24619865 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) consumption (75 mg EGCG)
Number of subjects: 24
Study 24619865 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 24
Study 24619865 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 24
Study 22578104 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity monitoring and distance counseling (n=264)
Number of subjects: 521
Study 22578104 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=257)
Number of subjects: 521
Study 19889063 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg)
Number of subjects: 484
Study 19889063 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 484
Study 18974808 — intervention group
Group type: EXPERIMENTAL
Intervention: Library and informatics training with emphasis on PubMed searching skills
Number of subjects: 60
Study 18974808 — intervention group
Group type: COMPARATOR
Intervention: Control group (identical training two weeks later)
Number of subjects: 60
Study 16482375 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine management service for diabetes patients
Number of subjects: 0
Study 16482375 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 0
Study 14557561 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g/day)
Number of subjects: 41
Study 14557561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 10823096 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg i.v.
Number of subjects: 90
Study 10823096 — intervention group
Group type: COMPARATOR
Intervention: Saline 2 ml i.v. (Control)
Number of subjects: 90
Study 9063788 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermagraft-TC (DG-TC)
Number of subjects: 66
Study 9063788 — intervention group
Group type: COMPARATOR
Intervention: Cryopreserved human cadaver skin (allograft)
Number of subjects: 66
Study 8363321 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangular rehabilitation (n = 13)
Number of subjects: 26
Study 8363321 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectangular rehabilitation (n = 13)
Number of subjects: 26
Study 8363321 — intervention group
Group type: COMPARATOR
Intervention: Both groups (triangular and rectangular)
Number of subjects: 26
Study 3783868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose diet (21% of energy as fructose)
Number of subjects: 24
Study 3783868 — intervention group
Group type: COMPARATOR
Intervention: Sucrose diet (23% of energy as sucrose)
Number of subjects: 24
Study 3783868 — intervention group
Group type: COMPARATOR
Intervention: Starch diet (almost all carbohydrate energy as starch)
Number of subjects: 24
Study 3783868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose diet
Number of subjects: 24
Study 3783868 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose diet
Number of subjects: 24
Study 31553815 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for targeted therapy-related fatigue (CBT-TTF)
Number of subjects: 44
Study 31553815 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 44
Study 28669554 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-check group
Number of subjects: 86
Study 28669554 — intervention group
Group type: COMPARATOR
Intervention: Single-check group
Number of subjects: 86
Study 27380540 — intervention group
Group type: EXPERIMENTAL
Intervention: Siponimod 10 mg
Number of subjects: 252
Study 27380540 — intervention group
Group type: EXPERIMENTAL
Intervention: Siponimod 2 mg
Number of subjects: 252
Study 27380540 — intervention group
Group type: EXPERIMENTAL
Intervention: Siponimod 1.25 mg
Number of subjects: 252
Study 27380540 — intervention group
Group type: EXPERIMENTAL
Intervention: Siponimod 0.5 mg
Number of subjects: 252
Study 27380540 — intervention group
Group type: EXPERIMENTAL
Intervention: Siponimod 0.25 mg
Number of subjects: 252
Study 27380540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 24920292 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal workload (VO2 max)
Number of subjects: 39
Study 24920292 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative workload (70% of VO2 max/10 min)
Number of subjects: 39
Study 24920292 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute workload (75W/10 min)
Number of subjects: 39
Study 24920292 — intervention group
Group type: COMPARATOR
Intervention: Pre-exercise
Number of subjects: 39
Study 22409920 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture intervention at acupoints Quchi (LI11) or Tianquan (PC2)
Number of subjects: 0
Study 22409920 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20356491 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent gemcitabine (1000 mg/m² at Days 1 and 8 for a 21-day cycle)
Number of subjects: 68
Study 20356491 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (gemcitabine 1000 mg/m² at Days 1 and 8 and carboplatin AUC5 at Day 2 for a 21-day cycle)
Number of subjects: 68
Study 18565577 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cessation intervention with $10 weekly incentives and personalized smoking cessation messages.
Number of subjects: 517
Study 18565577 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 517
Study 15976151 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT+fluoxetine
Number of subjects: 116
Study 15976151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 116
Study 15976151 — intervention group
Group type: COMPARATOR
Intervention: CBT+placebo
Number of subjects: 116
Study 15976151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 15976151 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT (any form)
Number of subjects: 116
Study 15976151 — intervention group
Group type: COMPARATOR
Intervention: No CBT
Number of subjects: 116
Study 12215588 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MRI (DWI)
Number of subjects: 54
Study 12215588 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 54
Study 10621762 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (200-300 mg/day)
Number of subjects: 122
Study 10621762 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (30-40 mg/day)
Number of subjects: 122
Study 8631039 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg daily
Number of subjects: 20
Study 8631039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1687407 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 831
Study 1687407 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 831
Study 1687407 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin
Number of subjects: 831
Study 1687407 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous beta-blockers
Number of subjects: 831
Study 1687407 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids before streptokinase infusion
Number of subjects: 831
Study 1687407 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin and oral anticoagulants
Number of subjects: 831
Study 6355181 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazoxiben 200 mg
Number of subjects: 0
Study 6355181 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazoxiben (25, 50, 100, 200 mg)
Number of subjects: 0
Study 6355181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30497093 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant administration (α-lipoic acid, vitamin C and E)
Number of subjects: 9
Study 30497093 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (30-s Wingate test)
Number of subjects: 9
Study 30497093 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant administration in hypoxia
Number of subjects: 9
Study 30497093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint exercise
Number of subjects: 9
Study 28204880 — intervention group
Group type: EXPERIMENTAL
Intervention: γ‐cyclodextrin curcumin formulation (CW8)
Number of subjects: 12
Study 28204880 — intervention group
Group type: EXPERIMENTAL
Intervention: curcumin phytosome formulation (CSL)
Number of subjects: 12
Study 28204880 — intervention group
Group type: COMPARATOR
Intervention: standardized unformulated curcumin extract (StdC)
Number of subjects: 12
Study 28204880 — intervention group
Group type: EXPERIMENTAL
Intervention: formulation of curcumin with essential oils of turmeric (CEO)
Number of subjects: 12
Study 27156027 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 75
Study 27156027 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 75
Study 23808990 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN α‐2b
Number of subjects: 1002
Study 23808990 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN α‐2b
Number of subjects: 1002
Study 21076897 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-posterior THA
Number of subjects: 22
Study 21076897 — intervention group
Group type: COMPARATOR
Intervention: Two-incision THA
Number of subjects: 22
Study 19884222 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 27
Study 19884222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 17483398 — intervention group
Group type: EXPERIMENTAL
Intervention: Focusing attention on others
Number of subjects: 3
Study 17483398 — intervention group
Group type: EXPERIMENTAL
Intervention: Focusing attention on group identity
Number of subjects: 3
Study 17483398 — intervention group
Group type: EXPERIMENTAL
Intervention: Focusing on individual values
Number of subjects: 3
Study 17483398 — intervention group
Group type: EXPERIMENTAL
Intervention: Focusing attention on others inducing perception of similarity with immigrants
Number of subjects: 3
Study 14984727 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 600 mg BID (n=23)
Number of subjects: 47
Study 14984727 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=24)
Number of subjects: 47
Study 11590517 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir (750 mg tid), saquinavir soft-gel capsule (SGC) (800 mg tid), and stavudine (40 mg bid)
Number of subjects: 73
Study 11590517 — intervention group
Group type: EXPERIMENTAL
Intervention: ritonavir (400 mg bid), saquinavir-SGC (400 mg bid), and stavudine (40 mg bid)
Number of subjects: 73
Study 11590517 — intervention group
Group type: EXPERIMENTAL
Intervention: delavirdine (400 mg tid), saquinavir-SGC (800 mg tid), and stavudine (40 mg bid)
Number of subjects: 73
Study 9833606 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1 g)
Number of subjects: 10
Study 9833606 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n=10)
Number of subjects: 10
Study 9833606 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ulcerative colitis
Number of subjects: 10
Study 8082093 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cisplatin (60 mg/m2) or carboplatin (300 mg/m2), epirubicin (50 mg/m2), etoposide (100 mg/m2) and local irradiation (15 Gy total)
Number of subjects: 58
Study 8082093 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin treatment
Number of subjects: 58
Study 8082093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin treatment
Number of subjects: 58
Study 8082093 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 58
Study 8082093 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders
Number of subjects: 58
Study 8082093 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 58
Study 2672755 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus relaxation and breathing therapy (treatment A, n = 76)
Number of subjects: 156
Study 2672755 — intervention group
Group type: COMPARATOR
Intervention: Exercise training only (treatment B, n = 80)
Number of subjects: 156
Study 2672755 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus relaxation and breathing therapy (treatment A)
Number of subjects: 156
Study 2672755 — intervention group
Group type: COMPARATOR
Intervention: Exercise training only (treatment B)
Number of subjects: 156
Study 31689378 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal dexmedetomidine
Number of subjects: 40
Study 31689378 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 40
Study 30945740 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper airway surgical procedure (modified uvulopalatopharyngoplasty and minimally invasive tongue volume reduction)
Number of subjects: 0
Study 30945740 — intervention group
Group type: COMPARATOR
Intervention: Ongoing medical management
Number of subjects: 0
Study 28795831 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy for Suicide Prevention (PST-SP)
Number of subjects: 16
Study 26335316 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled supraclavicular artery island flap (PSAIF)
Number of subjects: 27
Study 26335316 — intervention group
Group type: COMPARATOR
Intervention: Free radial forearm flap (FRFF)
Number of subjects: 27
Study 26335316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (PSAIF and FRFF)
Number of subjects: 27
Study 23190794 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 23190794 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0
Study 23190794 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol + Lisinopril
Number of subjects: 0
Study 23190794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21678494 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 429
Study 21678494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 18318746 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and physical programme
Number of subjects: 192
Study 18318746 — intervention group
Group type: COMPARATOR
Intervention: Control group (peripheral registry office and central tax office employees)
Number of subjects: 192
Study 17344670 — intervention group
Group type: COMPARATOR
Intervention: HD-LV5FU2
Number of subjects: 294
Study 17344670 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed (R)
Number of subjects: 294
Study 17344670 — intervention group
Group type: EXPERIMENTAL
Intervention: LD-LV5FU2
Number of subjects: 294
Study 17344670 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly infusional 5FU (WI-FU)
Number of subjects: 294
Study 12694772 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent-grafting (SG) performed under local anesthesia 9±3 days after CABG (simultaneous)
Number of subjects: 42
Study 12694772 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent-grafting (SG) performed during the same anesthesia (synchronous)
Number of subjects: 42
Study 10955433 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital pelvic floor contraction assessment using the Oxford Scale
Number of subjects: 263
Study 10955433 — intervention group
Group type: COMPARATOR
Intervention: Perineometric assessment using PFX perineometer
Number of subjects: 263
Study 8844389 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional silicone IOL (Group A)
Number of subjects: 240
Study 8844389 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher refractive index silicone IOL (Group B)
Number of subjects: 240
Study 8844389 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA IOL (Group C)
Number of subjects: 240
Study 8844389 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification without IOL (Group D)
Number of subjects: 240
Study 1740938 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative PCS patients
Number of subjects: 0
Study 1740938 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative PCS patients
Number of subjects: 0
Study 1740938 — intervention group
Group type: COMPARATOR
Intervention: Normal males
Number of subjects: 0
Study 6293716 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 1 (10% mannitol, oral neomycin, intravenous cefotaxime)
Number of subjects: 99
Study 6293716 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 2 (10% mannitol, oral neomycin, intravenous cefotaxime for 24 hours postoperatively)
Number of subjects: 99
Study 6293716 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 3 (10% mannitol, oral neomycin, cefazolin sodium)
Number of subjects: 99
Study 30798587 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation with sofosbuvir and ribavirin (Group B)
Number of subjects: 41
Study 30798587 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir plus ribavirin (Group A)
Number of subjects: 41
Study 28464438 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-facilitated intervention (TG)
Number of subjects: 15
Study 28464438 — intervention group
Group type: COMPARATOR
Intervention: Human-facilitated intervention (CG)
Number of subjects: 15
Study 25932701 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive EHR alert
Number of subjects: 28467
Study 25932701 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 28467
Study 23713245 — intervention group
Group type: EXPERIMENTAL
Intervention: Guizhi Fuling Pill (GFP) and earthworm powder (Group A)
Number of subjects: 408
Study 23713245 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (Group B)
Number of subjects: 408
Study 23713245 — intervention group
Group type: COMPARATOR
Intervention: Negative control (Group C)
Number of subjects: 408
Study 23713245 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (Group D)
Number of subjects: 408
Study 21554691 — intervention group
Group type: EXPERIMENTAL
Intervention: Public involvement in quality-indicator choice (direct participation and consultation)
Number of subjects: 27
Study 21554691 — intervention group
Group type: COMPARATOR
Intervention: Control group (only clinicians and managers involved in prioritisation)
Number of subjects: 27
Study 21554691 — intervention group
Group type: EXPERIMENTAL
Intervention: Public involvement intervention pilot test
Number of subjects: 27
Study 19540445 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique with burs and solvent (Group I)
Number of subjects: 40
Study 19540445 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional technique with burs and solvent plus clinical operating microscope/ultrasonic tips (Group II)
Number of subjects: 40
Study 17714175 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled trials identified in ABS database
Number of subjects: 47
Study 15185466 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based intervention (comprehensive education, prescribed diet, intensive pharmacological therapy)
Number of subjects: 418
Study 15185466 — intervention group
Group type: COMPARATOR
Intervention: Normally-discharged patients (control group)
Number of subjects: 418
Study 15185466 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based intervention
Number of subjects: 418
Study 11773907 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose milrinone (25 microg/kg intravenous bolus over 60 minutes followed by a 0.25 microg/kg/min infusion for 35 hours)
Number of subjects: 240
Study 11773907 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose milrinone (75 microg/kg intravenous bolus over 60 minutes followed by a 0.75 microg/kg/min infusion for 35 hours)
Number of subjects: 240
Study 11773907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 9650437 — intervention group
Group type: EXPERIMENTAL
Intervention: Standford Hypnotic Susceptibility Scale, Form C (SHSS:C) administered after cold pressor pain protocol
Number of subjects: 138
Study 9650437 — intervention group
Group type: COMPARATOR
Intervention: Standford Hypnotic Susceptibility Scale, Form C (SHSS:C) administered before cold pressor pain protocol
Number of subjects: 138
Study 7648148 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin plus metronidazole
Number of subjects: 169
Study 7648148 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin plus metronidazole
Number of subjects: 169
Study 7648148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cover for 3 days
Number of subjects: 169
Study 2667860 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (carisoprodol, paracetamol, and caffeine)
Number of subjects: 43